Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in Interest ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Marker Therapeutics (MRKR) over the last 11 years, with Q3 2025 value amounting to -$328316.0.

  • Marker Therapeutics' Change in Accured Expenses fell 11775.42% to -$328316.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.8 million, marking a year-over-year decrease of 20223.24%. This contributed to the annual value of $380845.0 for FY2024, which is 7135.76% down from last year.
  • Marker Therapeutics' Change in Accured Expenses amounted to -$328316.0 in Q3 2025, which was down 11775.42% from $245304.0 recorded in Q2 2025.
  • Marker Therapeutics' 5-year Change in Accured Expenses high stood at $2.9 million for Q2 2022, and its period low was -$4.0 million during Q1 2022.
  • Moreover, its 5-year median value for Change in Accured Expenses was $111171.0 (2023), whereas its average is $165790.5.
  • Examining YoY changes over the last 5 years, Marker Therapeutics' Change in Accured Expenses showed a top increase of 98214.76% in 2024 and a maximum decrease of 97764.79% in 2024.
  • Over the past 5 years, Marker Therapeutics' Change in Accured Expenses (Quarter) stood at $1.4 million in 2021, then plummeted by 173.65% to -$1.0 million in 2022, then skyrocketed by 193.32% to $961740.0 in 2023, then plummeted by 144.85% to -$431297.0 in 2024, then increased by 23.88% to -$328316.0 in 2025.
  • Its last three reported values are -$328316.0 in Q3 2025, $245304.0 for Q2 2025, and -$1.3 million during Q1 2025.